Curated news and analysis on clinical trials, drug approvals, and medical research.
A phase one trial of RSO-021 achieved disease control in 67% of relapsed mesothelioma patients. Other advances include daraxonrasib for NRAS-driven melanoma, an aneuploidy biomarker for PARP inhibitor response in childhood cancers, and new research into a cancer target and cholangiocarcinoma treatment.
IBBQ posted a 43.6% one-year return and 38% max drawdown, while IBB has $9.61B AUM and no dividends. IBBQ outperformed VHT and IXJ over one year but with higher volatility.
A Senate subcommittee heard testimony that mRNA COVID vaccines were considered the likely cause in 73.9% of post-vaccine deaths in a large autopsy series. Separately, NEJM research identified the K31E antibody mutation and adenovirus protein pVII as triggers of rare VITT blood clots. The findings may enable safer adenoviral vaccines.
In the Philippines, an estimated 7.3 million adults live with chronic hepatitis B, far above regional averages. Experts warn that complex treatment guidelines may hinder front-line clinicians from initiating care, while Thailand’s success with vaccination shows a path to elimination. Expanding screening and simplifying treatment are critical steps.
Institutional investors disclosed mixed moves in AstraZeneca plc during recent quarters, with several large funds selling while others initiated new positions. The company beat earnings expectations with $2.58 EPS and $15.29 billion in revenue. Analysts maintain a 'Moderate Buy' consensus with a $211.00 average price target.
Adjunct intra-arterial alteplase after thrombectomy improved 90-day functional recovery in LVO stroke (57.5% vs 42.5%). Headache occurs in 46% of hemorrhagic stroke patients; only 21.8% of stroke/TBI patients receive inpatient rehab.
Male nurses now represent 1 in 8 U.S. registered nurses, with growth concentrated in the South where shortages are acute. Recruitment efforts and shifting job-market perceptions are attracting more men, helping to meet a projected 189,000 annual openings.
New investment models and digital twin technologies are bridging gaps in rare disease drug development, where traditional funding and trial designs fall short. Patient-led funding and family offices provide capital, while regulators accept digital evidence to accelerate therapies for the more than 7,000 rare diseases with few approved treatments.
CaroMont Health is investing $200 million to expand cancer care, including a new Gastonia cancer center that will double oncology capacity to 3,000 patients per year. The center is planned to open in Fall 2028.
NASA's Artemis 2 SLS rocket is undergoing a second wet dress rehearsal after an earlier leak, while astronauts suit up and prepare for life in the Orion spacecraft. The 10-day mission around the moon could launch as soon as March 6.
New funding and research target antimicrobial resistance: £3.1m for Klebsiella discovery, an ERB antibiotic design, and a faster fidaxomicin test. India announced grants for fungal AMR research.
Recent drug investigations in New York and New Jersey led to more than a dozen arrests and seizures of fentanyl, cocaine, guns, and cash. Cases in Jersey City, Syracuse, Fallsburg, and Monticello resulted in numerous drug charges.
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
The FDA has refused to file Moderna's flu vaccine candidate mRNA-1010. The company will push forward outside the U.S. and pause its combination flu vaccine, while expressing disappointment over the decision's regulatory implications.
Institutional investors disclosed major changes to their AbbVie holdings as the stock hovers near record levels. AbbVie maintains a Moderate Buy analyst consensus with a $268.10 price target, buoyed by strong quarterly earnings and a newly declared dividend.
St. Jude Children’s Research Hospital experts are creating evidence-informed consensus guidelines covering brain tumor diagnosis, pharmacogenomics, survivorship care, and rare blood disorders. Their work helps clinicians translate the latest data into improved diagnosis, treatment, and follow-up care globally.
CDC and FDA are investigating a multistate outbreak of drug-resistant Salmonella linked to Rosabella moringa capsules. Seven people in seven states are infected; three hospitalized; no deaths.
China's pharma industry hit record clinical drug trials and out-licensing deal values in 2025 and H1 2026, with NMPA approvals surging. The growth has drawn US Senate scrutiny and new bipartisan oversight legislation.
